Testing a focused radiation approach for limited cancer spread
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at using a targeted form of radiation (LAT, often like SBRT) for people whose lung cancer has spread in only a few places while on osimertinib. It aims to control those “limited progression” spots and help you stay on the same medicine longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have advanced non-small cell lung cancer (NSCLC) with an EGFR mutation that you’re taking osimertinib for first treatment
- After about 3 months on osimertinib, scans showed at least stable disease (no clear overall worsening)
- Your cancer has progressed in 1 to 3 specific spots that the study team believes can be treated with the planned radiation; other spots must not be progressing
- Your overall health is strong enough for treatment (Karnofsky 60% or ECOG 0–2) and you’re expected to live at least 6 months
- You can have the planned treatment safely based on organ function tests, and you can sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding local treatments like radiation or surgery to standard immunotherapy can help people with lung cancer that has spread to a few spots. It aims to see if this combination improves control of the disease.
This trial tests whether adding targeted radiation or surgery to your regular osimertinib treatment can better control any remaining spots of lung cancer. It is for people with a specific EGFR mutation whose cancer has shrunk but left a few active sites.
This trial tests a new approach for patients with advanced non-small cell lung cancer that has a specific EGFR mutation (Ex19del or L858R) and has started to grow again after at least six months on osimertinib. It combines two types of focused radiation with continued osimertinib to treat only the progressing spots while keeping the rest of the disease under control.
This trial tests whether adding precise, high-dose radiation (SBRT) to the targeted therapy osimertinib can improve outcomes for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) that has shrunk but not disappeared on osimertinib alone.
This trial tests whether directly treating the remaining lung tumor with surgery or radiation, after initial chemo and osimertinib, can improve outcomes for people with advanced EGFR-mutant non-small cell lung cancer.
This trial tests a personalized treatment plan for advanced lung cancer with an EGFR mutation. It uses a blood test (ctDNA) to guide treatment with osimertinib (a targeted pill) plus chemotherapy. The goal is to see if adjusting therapy based on the blood test results can help you live longer with fewer side effects.
Hear when a new Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.